Roche Holdings (PK:RHHBY) Stock Upgrade
In a recent report revealed to investors on 2 December, Citigroup raised shares of Roche Holdings (PK:RHHBY) to a solid Buy rating from their previous Neutral rating.
Approximately 162,906 shares of stock traded hands. Roche Holding Ltd. (ADR) (PK:RHHBY) has declined 5.53% since April 29, 2015 and is downtrending. It has underperformed by 5.33% the S&P500.
Roche Holding AG is a research healthcare company. The company has a market cap of $234.15 billion. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. It has 25.86 P/E ratio. The Company’s Pharmaceuticals Division comprises the two business divisions: Roche Pharmaceuticals and Chugai.
According to Zacks Investment Research, “Roche Holding AG is a research-based, product-focused organization dedicated to the discovery and early clinical development of pharmaceuticals and drugs, fine chemicals and vitamins, fragrances and flavors, diagnostic equipment and liquid crystals. The Company distributes its products throughout Europe, the United States, Asia and Latin America.” Get a free copy of the Zacks research report on Roche Holding Ltd. (ADR) (RHHBY).